Daewoong Pharma대웅제약

Daewoong Pharma's trailing profits have recovered strongly, but the shares are down about 25% over the past year and trade near their 52-week low.

Trailing twelve-month revenue is about ₩1.64T with net income near ₩195B, and 2025 was a much stronger year than 2024 on both sales and profit. The share price has fallen sharply, and the filings and news in the data cover product launches, a lowered earnings outlook and a set of shareholder meeting and governance items. Free cash flow was negative on a trailing basis, and borrowings are large relative to cash.

What stands out

• Trailing profit recovered: net income is about ₩195B against ₩25B in 2024, and 2025 revenue grew 10.4% to about ₩1.57T.
• Trailing free cash flow was negative at about -₩104B, and borrowings of about ₩397B exceed cash of about ₩155B.
• The share price closed at ₩100,600, the same as its 52-week low, after a 25.1% fall over one year and a 21.6% fall over three months.
• Valuation looks low on trailing earnings, with a P/E of about 6 and P/B of 1.1, but the data gives no analyst targets to compare against.
• October news focused on the Fexuclue seven-day H. pylori regimen and Nabota expansion, while an October 14 report said the company lowered its earnings outlook as Pecsufly moves to direct sales.

What to watch

• Whether the lowered earnings outlook tied to the Pecsufly move to direct sales shows up in upcoming results.
• Filings on the August-September shareholder meeting items, the debt guarantee for another party and the lawsuit mentioned in the data.
• Debt levels and negative free cash flow, since liabilities are 113% of equity on a trailing basis.